Attached files

file filename
8-K - FORM 8-K CURRENT REPORT - LIBERATOR MEDICAL HOLDINGS, INC.f8k021015_8k.htm

EXHIBIT 99.1


Liberator Medical Reports Record Revenue of $20.2 Million for Its Fiscal First Quarter Ended December 31, 2014


The Company Reports Net Income of $2.4 Million, or $0.05 per Share, for the 3 Months Ended December 31, 2014 Up 14.2% Compared to the Same Period Last Year


STUART, FL -- (Marketwired) -- 02/09/15 -- Liberator Medical Holdings, Inc. (NYSE MKT: LBMH) today announced the financial results for its fiscal first quarter ended December 31, 2014.


Net sales for the three months ended December 31, 2014, increased by $1,579,000, or 8.5%, to $20,216,000, compared with net sales of $18,637,000 for the three months ended December 31, 2013. The increase in net sales was primarily due to our continued emphasis on our direct response advertising campaign to acquire new customers and our emphasis on customer service to maximize the reorder rates for our recurring customer base.


 

 

Three Months Ended December 31

Dollars in Thousands

 

Q1 FY2015

 

Q1 FY2014

 

%

Net Sales

 

$

20,216

 

$

18,637

 

8.5

Income from Operations

 

$

3,984

 

$

3,500

 

13.8

Net Income

 

$

2,421

 

$

2,120

 

14.2


Income from operations for the three months ended December 31, 2014, increased by $484,000, or 13.8%, to $3,984,000, compared with $3,500,000 for the three months ended December 31, 2013. The increase in operating income is primarily attributed to increased gross profits driven by our increased sales volumes as well as reductions in payroll costs as a percentage of net sales and decreased general and administration expenses.


Net income for the first quarter of fiscal year 2015 was $2,421,000 or $0.05 per diluted share, compared with net income of $2,120,000 or $0.04 per diluted share, for the first quarter of fiscal year 2013, an increase of 14.2%.


The Company had cash of $11,954,000 at December 31, 2014, compared with cash of $12,261,000 at September 30, 2014, a decrease of $307,000. The decrease in cash for the three months ended December 31, 2014, was due to $1,754,000 of cash used in financing activities and $13,000 of net cash used in investing activities, partially offset by $1,460,000 of cash provided by operating activities.


Mark Libratore, President and CEO, commented, "Our growth this quarter was driven by a 10% improvement in revenue from our existing customers. Customer retention has been and will continue to be a priority. Our improved operating margin was driven, in part by gains in labor productivity. We intend to continue to invest in operating efficiencies that streamline processes and improve quality. Our customers have many choices when it comes to their medical supplies and we will continue to find ways to improve their experience with Liberator."


Stay up-to-date with current events by visiting Liberator Medical's website at www.liberatormedical.com or by joining the Company's E-Mail Alert List. Join by clicking the following link www.LBMH-IR.com


About Liberator Medical Holdings, Inc.


Liberator Medical Holdings, Inc.'s subsidiary, Liberator Medical Supply, Inc., established the Liberator brand as a leading national direct-to-consumer provider of quality medical supplies to Medicare-eligible seniors. Accredited by The Joint Commission, our Company's unique combination of marketing, industry expertise and customer service has demonstrated success over a broad spectrum of chronic conditions. Liberator is recognized for offering a simple, reliable way to purchase medical supplies needed on a regular, ongoing, repeat-order basis, with the convenience of direct billing to Medicare and private insurance. Liberator's revenue primarily comes from supplying products to meet the rapidly growing requirements of general medical supplies, diabetes supplies, catheters, ostomy supplies and mastectomy fashions. Liberator communicates with patients and their doctors on a regular basis regarding prescriptions and supplies. Customers may purchase by phone, mail or internet, with repeat orders confirmed with the customer and shipped when needed.





Safe Harbor Statement


In this press release and in related comments by our management, our use of the words "expect," "anticipate," "possible," "potential," "target," "believe," "commit," "intend," "continue," "may," "would," "could," "should," "project," "projected," "positioned" or similar expressions is intended to identify forward-looking statements that represent our current judgment about possible future events. We believe these judgments are reasonable, but these statements are not guarantees of any events or financial results, and our actual results may differ materially due to a variety of important factors. Such risks and uncertainties may include, but are not limited to, regulatory limitations on the medical industry in general, working capital constraints, fluctuations in customer demand and commitments, fluctuation in quarterly results, introduction of new services and products, commercial acceptance and viability of new services and products, pricing and competition, reliance upon subcontractors and vendors, the timing of new technology and product introductions, and the risk of early obsolescence of our products. Liberator's most recent annual report on Form 10-K and quarterly reports on Form 10-Q provide information about these and other factors, which we may revise or supplement in future reports filed with the Securities and Exchange Commission.



2




Liberator Medical Holdings, Inc. and Subsidiaries

Condensed Consolidated Balance Sheets

As of December 31, 2014 (unaudited) and September 30, 2014

(In thousands, except dollar per share amounts)


 

 

December 31, 2014

 

September 30, 2014

Assets

 

 

 

 

 

 

Current Assets:

 

 

 

 

 

 

Cash

 

$

11,954

 

$

12,261

Accounts receivable, net of allowances of $4,617 and $4,569, respectively

 

 

9,606

 

 

8,866

Inventory, net of allowance for obsolete inventory of $181

 

 

2,078

 

 

1,954

Deferred tax assets

 

 

2,033

 

 

2,005

Prepaid and other current assets

 

 

716

 

 

449

Total Current Assets

 

 

26,387

 

 

25,535

Property and equipment, net of accumulated depreciation of $4,106 and $4,016, respectively

 

 

1,210

 

 

1,260

Deferred advertising, net

 

 

28,342

 

 

26,936

Intangible assets, net of accumulated amortization of $310 and $281, respectively

 

 

391

 

 

420

Other assets

 

 

164

 

 

178

Total Assets

 

$

56,494

 

$

54,329

 

 

 

 

 

 

 

Liabilities and Stockholders' Equity

 

 

 

 

 

 

Current Liabilities:

 

 

 

 

 

 

Accounts payable

 

$

6,187

 

$

6,085

Accrued liabilities

 

 

1,554

 

 

1,758

Dividends payable

 

 

1,728

 

 

1,728

Income tax payable

 

 

1,322

 

 

178

Other current liabilities

 

 

150

 

 

161

Total Current Liabilities

 

 

10,941

 

 

9,910

Deferred tax liabilities

 

 

10,449

 

 

10,031

Credit line facility

 

 

1,500

 

 

1,500

Other long-term liabilities

 

 

468

 

 

453

Total Liabilities

 

 

23,358

 

 

21,894

 

 

 

 

 

 

 

Commitments and contingencies (see Note 7)

 

 

 

 

 

 

 

 

 

 

 

 

 

Stockholders' Equity:

 

 

 

 

 

 

Common stock, $0.001 par value, 200,000 shares authorized, 53,520 shares issued and 53,166 shares outstanding at December 31, 2014, and September 30, 2014

 

 

54

 

 

54

Additional paid-in capital

 

 

36,393

 

 

36,385

Accumulated deficit

 

 

(2,831)

 

 

(3,524)

Treasury stock, at cost; 354 shares at December 31, 2014, and September 30, 2014

 

 

(480)

 

 

(480)

Total Stockholders' Equity

 

 

33,136

 

 

32,435

Total Liabilities and Stockholders' Equity

 

$

56,494

 

$

54,329


See accompanying notes to unaudited condensed consolidated financial statements.



3




Liberator Medical Holdings, Inc. and Subsidiaries

Condensed Consolidated Statements of Operations

For the three months ended December 31, 2014 and 2013

(Unaudited)

(in thousands, except per share amounts)


 

 

Three Months Ended December 31,

 

 

2014

 

2013

 

 

 

 

 

 

 

Net Sales

 

$

20,216

 

$

18,637

 

 

 

 

 

 

 

Cost of Sales

 

 

7,585

 

 

6,882

 

 

 

 

 

 

 

Gross Profit

 

 

12,631

 

 

11,755

 

 

 

 

 

 

 

Operating Expenses:

 

 

 

 

 

 

Payroll, taxes and benefits

 

 

3,762

 

 

3,657

Advertising

 

 

2,615

 

 

2,326

Bad debts

 

 

943

 

 

824

Depreciation and amortization

 

 

119

 

 

171

General and administrative

 

 

1,208

 

 

1,277

Total Operating Expenses

 

 

8,647

 

 

8,255

 

 

 

 

 

 

 

Income from Operations

 

 

3,984

 

 

3,500

 

 

 

 

 

 

 

Other Expenses

 

 

(12)

 

 

(13)

 

 

 

 

 

 

 

Income before Income Taxes

 

 

3,972

 

 

3,487

 

 

 

 

 

 

 

Provision for Income Taxes

 

 

1,551

 

 

1,367

 

 

 

 

 

 

 

Net Income

 

$

2,421

 

$

2,120

 

 

 

 

 

 

 

Basic earnings per share:

 

 

 

 

 

 

Weighted average shares outstanding

 

 

53,166

 

 

52,358

Earnings per share

 

$

0.05

 

$

0.04

 

 

 

 

 

 

 

Diluted earnings per share:

 

 

 

 

 

 

Weighted average shares outstanding

 

 

53,695

 

 

53,228

Earnings per share

 

$

0.05

 

$

0.04

 

 

 

 

 

 

 

Dividends declared per common share

 

$

0.03

 

$

0.03


See accompanying notes to unaudited condensed consolidated financial statements.



4




Liberator Medical Holdings, Inc. and Subsidiaries

Condensed Consolidated Statements of Cash Flows

For the three months ended December 31, 2014 and 2013

(Unaudited)

(in thousands)


 

 

Three Months Ended December 31,

 

 

2014

 

2013

 

 

 

 

 

 

 

Cash flow from operating activities:

 

 

 

 

 

 

Net Income

 

$

2,421

 

$

2,120

Adjustments to reconcile net income to net cash provided by operating activities:

 

 

 

 

 

 

Depreciation and amortization

 

 

2,717

 

 

2,482

Equity based compensation

 

 

8

 

 

32

Provision for doubtful accounts and contractual adjustments

 

 

927

 

 

1,027

Deferred income taxes

 

 

390

 

 

(120)

Reserve for inventory obsolescence

 

 

-

 

 

13

Changes in operating assets and liabilities:

 

 

 

 

 

 

Accounts receivable

 

 

(1,667)

 

 

(2,779)

Deferred advertising

 

 

(4,004)

 

 

(2,918)

Inventory

 

 

(124)

 

 

(307)

Other assets

 

 

(260)

 

 

(402)

Income taxes prepaid and payable

 

 

1,150

 

 

486

Accounts payable

 

 

101

 

 

1,466

Accrued liabilities

 

 

(204)

 

 

215

Other liabilities

 

 

5

 

 

(8)

Net Cash Flow Provided by Operating Activities

 

 

1,460

 

 

1,307

 

 

 

 

 

 

 

Cash flow from investing activities:

 

 

 

 

 

 

Purchase of property and equipment

 

 

(13)

 

 

(51)

Proceeds from sale of property and equipment

 

 

-

 

 

4

Net Cash Flow Used in Investing Activities

 

 

(13)

 

 

(47)

 

 

 

 

 

 

 

Cash flow from financing activities:

 

 

 

 

 

 

Proceeds from exercise of employee stock options

 

 

-

 

 

72

Cash dividends paid

 

 

(1,728)

 

 

(1,569)

Payments of capital lease obligations

 

 

(26)

 

 

(21)

Net Cash Flow Used in Financing Activities

 

 

(1,754)

 

 

(1,518)

 

 

 

 

 

 

 

Net decrease in cash

 

 

(307)

 

 

(258)

 

 

 

 

 

 

 

Cash at beginning of period

 

 

12,261

 

 

12,453

Cash at end of period

 

$

11,954

 

$

12,195

 

 

 

 

 

 

 

Supplemental disclosure of cash flow information:

 

 

 

 

 

 

Cash paid for interest

 

$

12

 

$

15

Cash paid for income taxes

 

$

10

 

$

1,000

 

 

 

 

 

 

 

Supplemental schedule of non-cash financing activities:

 

 

 

 

 

 

Capital expenditures funded by capital lease borrowings or term notes

 

$

26

 

$

-

Cash dividends declared, but not yet paid

 

$

1,728

 

$

1,572


See accompanying notes to unaudited condensed consolidated financial statements.



5




Contacts:


Individual Investor Relations Contact

WSR Communications

772-219-7525

IR@WSRcommunications.com

http://ir.liberatormedical.com/


Institutional Investor Contact

Robert J. Davis

Liberator Medical Holdings, Inc.

772-463-3737

bdavis@liberatormedical.com

http://ir.liberatormedical.com/


Source: Liberator Medical Holdings, Inc.


Released February 9, 2015




6